Atossa Therapeutics enters at-the-market equity facility for up to $100M

ATOSSA THERAPEUTICS, INC.

Agreement with Jefferies LLC dated Nov 19, 2024 to sell up to $100M of common stock at-the-market.
Commission to Jefferies is up to 3.0% of gross proceeds; company reimburses certain expenses.
Proceeds intended for clinical development, working capital, and general corporate purposes.
No obligation to sell any shares; company may suspend or terminate the agreement at any time.
Shares registered under effective S-3 filed May 13, 2024; prospectus supplement filed Nov 19, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.